# OnCo record itil-168 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/itil-168/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "itil-168" ;
  schema:name "ITIL-168"@en ;
  schema:description "ITIL-168 is an autologous tumour-infiltrating lymphocyte cell therapy from Instil Bio that reached phase 2 for advanced cutaneous melanoma, cervical cancer and head and neck squamous cell carcinoma and other cancers; development has stopped."@en ;
  schema:url <https://onco.cc/drugs/itil-168/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/1789769/000178976926000019/til-20251231.htm>, <https://clinicaltrials.gov/api/v2/studies/NCT05050006>, <https://clinicaltrials.gov/search?intr=ITIL-168> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest", "discontinued" ;
  onco:modality "Autologous tumour-infiltrating lymphocyte (TIL) cell therapy" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/nsclc/> ;
  onco:companies <https://onco.cc/companies/instil-bio/> ;
  onco:trials <https://onco.cc/trials/nct05050006/>, <https://onco.cc/trials/nct05393635/> .